230 related articles for article (PubMed ID: 19002040)
1. Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution.
Ovanesov MV; Panteleev MA; Sinauridze EI; Kireev DA; Plyushch OP; Kopylov KG; Lopatina EG; Saenko EL; Ataullakhanov FI
Blood Coagul Fibrinolysis; 2008 Dec; 19(8):743-55. PubMed ID: 19002040
[TBL] [Abstract][Full Text] [Related]
2. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation.
Gerotziafas GT; Chakroun T; Depasse F; Arzoglou P; Samama MM; Elalamy I
Thromb Haemost; 2004 May; 91(5):977-85. PubMed ID: 15116259
[TBL] [Abstract][Full Text] [Related]
3. Recombinant factor VIIa does not induce hypercoagulability in vitro.
Gallistl S; Cvirn G; Muntean W
Thromb Haemost; 1999 Feb; 81(2):245-9. PubMed ID: 10064000
[TBL] [Abstract][Full Text] [Related]
4. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
Hoffman M; Monroe DM
Dis Mon; 2003 Jan; 49(1):14-21. PubMed ID: 12525825
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of factor VIIa-dependent coagulation in hemophilia blood.
Butenas S; Brummel KE; Branda RF; Paradis SG; Mann KG
Blood; 2002 Feb; 99(3):923-30. PubMed ID: 11806995
[TBL] [Abstract][Full Text] [Related]
6. Tissue factor-independent effects of recombinant factor VIIa on hemostasis.
Weeterings C; Lisman T; de Groot PG
Semin Hematol; 2008 Apr; 45(2 Suppl 1):S12-5. PubMed ID: 18544417
[TBL] [Abstract][Full Text] [Related]
7. Improvement of spatial fibrin formation by the anti-TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation.
Parunov LA; Fadeeva OA; Balandina AN; Soshitova NP; Kopylov KG; Kumskova MA; Gilbert JC; Schaub RG; McGinness KE; Ataullakhanov FI; Panteleev MA
J Thromb Haemost; 2011 Sep; 9(9):1825-34. PubMed ID: 21696535
[TBL] [Abstract][Full Text] [Related]
8. Blood coagulation in hemophilia A and hemophilia C.
Cawthern KM; van 't Veer C; Lock JB; DiLorenzo ME; Branda RF; Mann KG
Blood; 1998 Jun; 91(12):4581-92. PubMed ID: 9616154
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of hemostatic status in four patients being treated with recombinant factor VIIa.
Carr ME; Martin EJ; Kuhn JG; Ambrose H; Fern S; Bryant PC
Clin Lab; 2004; 50(9-10):529-38. PubMed ID: 15481628
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa.
van 't Veer C; Golden NJ; Mann KG
Blood; 2000 Feb; 95(4):1330-5. PubMed ID: 10666207
[TBL] [Abstract][Full Text] [Related]
11. A possible mechanism of action of activated factor VII independent of tissue factor.
Monroe DM; Hoffman M; Oliver JA; Roberts HR
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S15-20. PubMed ID: 9819024
[TBL] [Abstract][Full Text] [Related]
12. In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel.
Mazzeffi M; Szlam F; Jakubowski JA; Tanaka KA; Sugidachi A; Levy JH
Thromb Res; 2013 Jul; 132(1):106-11. PubMed ID: 23664633
[TBL] [Abstract][Full Text] [Related]
13. Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIa.
Eichinger S; Lubsczyk B; Kollars M; Traby L; Zwiauer K; Gleiss A; Quehenberger P; Kyrle PA
Eur J Clin Invest; 2009 Aug; 39(8):707-13. PubMed ID: 19490067
[TBL] [Abstract][Full Text] [Related]
14. A novel approach to improving recombinant factor VIIa activity with a preserved platelet preparation.
Campbell RA; Fischer TH; Wolberg AS
Br J Haematol; 2007 Jul; 138(1):82-93. PubMed ID: 17555451
[TBL] [Abstract][Full Text] [Related]
15. Platelet-dependent thrombin generation assay for monitoring the efficacy of recombinant Factor VIIa.
Wegert W; Harder S; Bassus S; Kirchmaier CM
Platelets; 2005 Feb; 16(1):45-50. PubMed ID: 15763896
[TBL] [Abstract][Full Text] [Related]
16. Recombinant factor VIIa addition to haemophilic blood perfused over collagen/tissue factor can sufficiently bypass the factor IXa/VIIIa defect to rescue fibrin generation.
Li R; Panckeri KA; Fogarty PF; Cuker A; Diamond SL
Haemophilia; 2017 Sep; 23(5):759-768. PubMed ID: 28475272
[TBL] [Abstract][Full Text] [Related]
17. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion.
Carr ME; Martin EJ; Kuhn JG; Seremetis SV
Thromb Haemost; 2003 May; 89(5):803-11. PubMed ID: 12719776
[TBL] [Abstract][Full Text] [Related]
18. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia.
Allen GA; Persson E; Campbell RA; Ezban M; Hedner U; Wolberg AS
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):683-9. PubMed ID: 17204663
[TBL] [Abstract][Full Text] [Related]
19. Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI.
Livnat T; Zivelin A; Martinowitz U; Salomon O; Seligsohn U
J Thromb Haemost; 2006 Jan; 4(1):192-200. PubMed ID: 16409469
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of a recombinant fusion protein linking activated coagulation factor VII with human albumin (rVIIa-FP) in patients with congenital FVII deficiency.
Gorkom BL; Holme PA; Joch C; Rogosch T; Feussner A; McKeand W; Roberts J; van Heerde W
Hematology; 2020 Dec; 25(1):17-25. PubMed ID: 31852380
[No Abstract] [Full Text] [Related]
[Next] [New Search]
